
    
      A Double-Blind, Randomized, Placebo-Controlled, Multi-Centre, Dose-Ranging, Parallel Group,
      Phase II Study to Assess Efficacy, Safety/Tolerability, and Pharmacokinetics of a
      Thrombopoietin Receptor Agonist, SB-497115-GR, when Administered as 30, 50, and 75 mg Once
      Daily for 12 weeks in Subjects with Chronic Hepatitis C-Related Thrombocytopenia who are
      Potential Candidates for Antiviral Treatment with Pegylated Interferon and Ribavirin.
    
  